Moreover, related non-brain-penetrant inhibitors might find application in G2019S-LRRK2 mutation carriers at increased risk for breast cancer as a potential anti-cancer agent acting solely in the periphery. This evidence concerns the gene LRRK2 and breast carcinoma.